MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2024-25)
- Udyam number
- UDYAM-MH-19-0000753
Jindal Drugs Private Limited - chemicals and materials in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹418.88 Cr
▲ 26% YoY
Net profit · FY 2025
₹92.21 Cr
Net margin 22%
EBITDA · FY 2025
₹151.91 Cr
EBITDA margin 36.3%
Authorised capital
₹27.26 Cr
Registered with MCA
Paid-up capital
₹11.96 Cr
Issued & subscribed
Open charges
₹696 Cr
Satisfied ₹797.98 Cr
Company age
44 yrs
Est. 1982
Employees · EPFO
47
Provident fund records
About Jindal Drugs Private Limited
Data last updated:
Jindal Drugs Private Limited is a private limited company based in Mumbai, Maharashtra, India. It operates in the specialty chemicals segment of the chemicals and materials sector. It was incorporated on 04 November 1982 and has been in existence for over 44 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24114MH1982PTC028621. Its GSTIN is 27AAACJ1000A1ZN (Maharashtra). The company holds 8 GST registrations, of which 4 are active.
The company has an authorised share capital of ₹27.26 Cr and a paid-up capital of ₹11.96 Cr. It was formerly known as Jindal Dye Intermediate Limited and Jindal Dye Intermediate Private Limited. It is led by directors including Ajay Shrikrishan Jindal (Managing Director) and Mamta Ajay Jindal (Whole-Time Director).
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 12A Bakhtawar 12th Floor 229 Nariman Point, Mumbai, Maharashtra, India – 400021.
As per the financials filed for FY 2025, the company reported a revenue of ₹418.88 Cr, a growth of 26% compared to the previous year. For the same year it recorded a net profit of ₹92.21 Cr (net margin 22%) and EBITDA of ₹151.91 Cr (EBITDA margin 36.3%). Revenue has grown at a compounded annual rate (CAGR) of 1% over five years.
The company has about 47 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.
The company is associated with 1 brand: Jindal Drugs. As per MCA filings, the company has open charges of ₹696 Cr and satisfied charges of ₹797.98 Cr on record. Court records list 353 cases involving the company, including 211 filed by the company and 142 filed against it; 63 cases are pending. The company has 4 deals on record (4 secondary share transfers); the latest was in September 2021. The company has 1 MSME Form 1 return on record for the period ending Mar 2024, listing 13 overdue payments to 13 micro and small suppliers.
Jindal Drugs Private Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-19-0000753). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website jindaldrugs.com.
Company details
CIN U24114MH1982PTC028621
Registration Number 028621
Incorporation Date 04 November 1982
ROC Mumbai
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-MH-19-0000753
Name history
Jindal Drugs has undergone 3 name changes throughout its history. The company was previously known as Jindal Dye Intermediate Limited, Jindal Dye Intermediate Private Limited, and Jindal Drugs Limited. The current legal name is Jindal Drugs Private Limited.
| Company Name | Status |
|---|---|
| Jindal Drugs Private Limited | Current |
| Jindal Dye Intermediate Limited | Previous |
| Jindal Dye Intermediate Private Limited | Previous |
| Jindal Drugs Limited | Previous |
CIN history
Jindal Drugs has one previous CIN (Corporate Identification Number): U24114MH1982PLC028621. The current CIN is U24114MH1982PTC028621, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24114MH1982PTC028621 | Current |
| U24114MH1982PLC028621 | Previous |
Key People
Ajay Shrikrishan Jindal Managing Director Mamta Ajay Jindal Whole-Time Director Ishaan Jindal Whole-Time Director Recognitions & Rankings of Jindal Drugs
Contact details
Jindal Drugs Private Limited's registered office is in Mumbai, Maharashtra. Its website is jindaldrugs.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address12A Bakhtawar 12th Floor 229 Nariman Point, Mumbai, Maharashtra, India – 400021
- IndustryChemicals and Materials, Specialty Chemicals
To see the full contact details of Jindal Drugs Private Limited, buy the company report.
Comprehensive company report
Jindal Drugs Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Jindal Drugs operates one associated brand: Jindal Drugs. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Manufacturing and exporting of essential oils and derivatives in India. | jindaldrugs.com |
Business activity
The main business activity of Jindal Drugs is manufacturing. In detail, this covers other manufacturing including jewellery, musical instruments, medical instruments, sports goods, etc. activities.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C13 | Other manufacturing including jewellery, musical instruments, medical instruments, sports goods, etc. activities |
To see the full business activity and turnover split of Jindal Drugs Private Limited, buy the company report.
Financials of Jindal Drugs Private Limited
FY 2025 filings availableJindal Drugs Private Limited reported revenue of ₹418.88 Cr (up 26% YoY) for FY 2025.
Revenue · FY 2025
₹418.88 Cr ▲ 26%
Net profit · FY 2025
₹92.21 Cr margin 22%
EBITDA · FY 2025
₹151.91 Cr margin 36.3%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 26%
5 years · compounded
▲ 1%
EBITDA CAGR growth
1 year
▲ 29%
Revenue has grown at a compounded annual rate (CAGR) of 1% over five years, including 26% growth in the latest year. EBITDA rose 29% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹151.91 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹92.21 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 36.3% | ||||
| Net Profit Margin | 22% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Jindal Drugs Private Limited, buy the company report.
Board of directors of Jindal Drugs Private Limited
Jindal Drugs has 6 current directors and 8 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Mamta Ajay Jindal | Whole-Time Director | 23 Mar 2015 | 11 Years 7 Months | Current |
| Ishaan Jindal Also directs: Eskay Management Services Pvt Ltd | Whole-Time Director | 08 Jul 2019 | 7 Years 3 Months | Current |
| Ajay Shrikrishan Jindal Also directs: Jindal Multitrade Private Limited, Jogmaz Holding and Investments Private Limited, Eskay Management Services Pvt Ltd and 1 more | Managing Director | 01 Oct 2011 | 15 Years 0 Months | Current |
| Shrikrishan Parameshwaridas Jindal | Whole-Time Director | 01 Oct 2011 | 15 Years 0 Months | Current |
| Krishnabai Shrikrishan Jindal | Whole-Time Director | 23 Mar 2015 | 11 Years 7 Months | Current |
| Aashna Ajay Jindal | Whole-Time Director | 24 Oct 2017 | 9 Years 0 Months | Current |
Auditor
Jindal Drugs Private Limited is audited by MSKA & Associates for the financial year 2021.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| MSKA & Associates | FY 2021 | 105047W |
Shareholding
The shareholding of Jindal Drugs Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Jindal Drugs Private Limited, buy the company report.
Charges & borrowings
Open charges
₹696 Cr
Satisfied charges
₹797.98 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 09 May 2025 | 101099714 | Others | ₹30 Cr | Open | |
| 31 Oct 2022 | 100653162 | Others | ₹50 Cr | Open | |
| 25 Mar 2014 | 10488870 | Sbicap Trustee Company Limited | ₹600 Cr | Open | |
| 19 Jul 1998 | 90186596 | Oversea- Chinese Banking Corp Ltd | ₹8 Cr | Open | |
| 14 Jul 1998 | 90184095 | Oversea- Chinese Banking Corp Ltd | ₹8 Cr | Open |
To see the full charge records of Jindal Drugs Private Limited, buy the company report.
Total charge records: 38 View all charges
Deals & funding
Jindal Drugs Private Limited has 4 deals on record (4 secondary share transfers); the latest was in September 2021.
Total deals
4
Secondary share transfers
4
Deals on record (4 of 4)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Sep 2021 | Secondary share transfer | Undisclosed | Seller: an individual |
| Mar 2021 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Nov 2018 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: 2 individuals |
| Nov 2018 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: Shrikrishan Jindal HUF |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Jindal Drugs Private Limited has 353 court cases on record: 211 filed by Jindal Drugs, 142 filed against it. 63 cases are pending and 290 are disposed.
Total cases
353
Filed by the company
211
Filed against the company
142
Pending
63
Disposed
290
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 236 | 98 | 46 |
| District courts | 76 | 25 | 9 |
| Supreme Court | 41 | 19 | 8 |
Cases on record (5 of 353)
| Court | Type of case | Party | Status |
|---|---|---|---|
| Supreme Court | Court case (2406-Indirect Taxation : Goods and Services Tax, Integrated Goods and Services Tax, State Goods and Services Tax, UT Goods and Services Tax.) | Filed against the company by Union of India and 97 others | Disposed |
| Bombay High Court | Interim or miscellaneous application | Filed by the company against V J Jindal Cocoa Private Limited and 1 other | Pending |
| High Court, GUJARAT | Appeal | Filed by the company against Finex Sieves Pvt Ltd and 1 other | Pending |
| Bombay High Court | Interim or miscellaneous application | Filed against the company | Pending |
| Bombay High Court | Tax appeal | Filed against the company by PR Commissioner of Income Tax 3 Mumbai | Pending |
To see the full case history of Jindal Drugs Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Jindal Drugs Private Limited has 1 MSME Form 1 return on record for the period ending Mar 2024, listing 13 overdue payments to 13 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 13)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| Sawant Filtech Private Limited | |||
| Cargo Pack Private Limited | |||
| Indial Shipping Private Limited | |||
| an individual supplier |
To see the full MSME payment records of Jindal Drugs Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Jindal Drugs has 1 subsidiary company. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
1
Subsidiary companies
Key subsidiaries
| Company Name | CIN | Shares held |
|---|---|---|
| Jindal Multitrade Private Limited | U65923MH2013PTC251430 |
To see the full group structure of Jindal Drugs Private Limited, buy the company report.
Employees & EPFO
Jindal Drugs Private Limited has a workforce of 47 employees on its EPFO records as of Mar 31, 2024, across 2 active EPFO establishments.
Employee count
47
Active EPFO establishments
2
Employee growth
-6%
GST
Jindal Drugs has 8 GST registrations: 4 active and 4 cancelled or inactive.
Total GSTINs
8
Active
4
Cancelled / inactive
4
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAACJ1000A1ZN | Maharashtra | Active | 01 Jul 2017 |
| 09AAACJ1000A1ZL | Uttar Pradesh | Active | 01 Jul 2017 |
| 01AAACJ1000A4ZY | Jammu and Kashmir | Active | 12 Oct 2017 |
| 26AAACJ1000A1ZP | Daman & Diu | Active | 01 Aug 2020 |
To see the full GST registrations and return filing status of Jindal Drugs Private Limited, buy the company report.
Recent activity
Jindal Drugs Private Limited has 13 board changes on record since 2011: 6 appointments and 7 cessations. The latest: Ishaan Jindal ceased to be Director on 30 Sep 2025.
Charges
A charge with Others of Rs. 30.00 Cr registered on 09 May 2025 with Charge ID 101099714 was modified on 25 Nov 2025.
AGM
Jindal Drugs Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Ceased
Ishaan Jindal ceased to be Director.
Charges
A charge with Others amounted to Rs. 30.00 Cr with Charge ID 101099714 was registered on 09 May 2025.
Filing
Jindal Drugs Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai.
Charges
A charge registered on 17 Jun 2020 via Charge ID 100344503 with Others was fully satisfied on 11 Jan 2023.
Charges
A charge with Others amounted to Rs. 50.00 Cr with Charge ID 100653162 was registered on 31 Oct 2022.
Charges
A charge with Others amounted to Rs. 9.09 Cr with Charge ID 100344503 was registered on 17 Jun 2020.
Charges
A charge registered on 05 Feb 1996 via Charge ID 90186310 with Idbi Bank was fully satisfied on 08 Nov 2019.
Charges
A charge registered on 04 Oct 1995 via Charge ID 90186257 with Idbi was fully satisfied on 08 Nov 2019.
Charges
A charge registered on 13 Oct 2001 via Charge ID 90229716 with Canara Bank was fully satisfied on 26 Aug 2019.
Charges
A charge registered on 19 Jan 1998 via Charge ID 90156772 with Canara Bank was fully satisfied on 26 Aug 2019.
86 earlier events are in the company report.
Frequently asked questions
Jindal Drugs is an active private limited company based in Mumbai, Maharashtra, India. The company works in specialty chemicals, within the chemicals and materials industry. It was incorporated on 04 November 1982 (44+ years old) and is registered under CIN U24114MH1982PTC028621.
Jindal Drugs has 6 current directors:
- Ajay Shrikrishan Jindal - Managing Director
- Mamta Ajay Jindal - Whole-Time Director
- Ishaan Jindal - Whole-Time Director
- Shrikrishan Parameshwaridas Jindal - Whole-Time Director
- Krishnabai Shrikrishan Jindal - Whole-Time Director
- Aashna Ajay Jindal - Whole-Time Director
The latest financial statements of Jindal Drugs on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Jindal Drugs is 27AAACJ1000A1ZN, registered in Maharashtra. The company has 8 GST registrations in all, of which 4 are active and 4 are cancelled or inactive. Other active GSTINs include 09AAACJ1000A1ZL (Uttar Pradesh), 01AAACJ1000A4ZY (Jammu and Kashmir), 26AAACJ1000A1ZP (Daman & Diu).
The CIN (Corporate Identification Number) of Jindal Drugs is U24114MH1982PTC028621. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Jindal Drugs has 353 court cases on record: 211 filed by the company and 142 filed against it. 63 are pending. Most are in the high courts.
Jindal Drugs was incorporated on 04 November 1982, making it 44+ years old. It is registered with the Registrar of Companies, Mumbai.
Jindal Drugs has 4 deals on record (4 secondary share transfers); the latest was in September 2021.
Ishaan Jindal ceased to be Director on 30 Sep 2025. Ishaan Jindal was appointed as Whole-Time Director on 08 Jul 2019. Aashna Ajay Jindal ceased to be Director on 14 Nov 2017. Jindal Drugs has 13 board changes on record in total.
Yes, Jindal Drugs is registered as a medium enterprise under Udyam registration (number: UDYAM-MH-19-0000753).
Jindal Drugs has 1 MSME Form 1 return on record for the period ending Mar 2024, listing 13 overdue payments to 13 micro and small suppliers. The latest return was filed on 25 Apr 2024.